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1  | INTRODUC TION
The alternative pathway (AP) of the complement system is vital to 
host defense against pathogens yet also contributes to autoimmune 
and inflammatory diseases. In host defense, the effects of comple-
ment activation are largely dependent on the cleavage of C3 by the 
C3 convertases, enzyme complexes assembled during complement 
activation (Figure 1A). C3 cleavage products opsonize targets for 
clearance by phagocytic cells, promote inflammation, and perturb 
cell surfaces via the membrane attack complex (MAC; C5b- 9).
Regulation of convertase activity is required to maintain homeo-
stasis and protect self- tissue. Membrane cofactor protein (MCP; 
CD46) and decay accelerating factor (DAF; CD55) are proteins ex-
pressed on most healthy cells that regulate convertases. Factor H 
(FH) is an abundant plasma protein that prevents formation of and 
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Problem: Crry is a widely expressed type 1 transmembrane complement regulatory 
protein in rodents which protects self- tissue by downregulating C3 activation. Crry−/− 
concepti produced by Crry+/− × Crry+/− matings are attacked by maternal complement 
system leading to loss before day 10. The membrane attack complex is not the me-
diator of this death. We hypothesized that the ability of C3b to engage the alternative 
pathway’s feedback loop relatively unchecked on placental membranes induces the 
lesion yielding the demise of the Crry−/− mouse.
Method of Study: We investigated the basis of Crry−/− conceptus demise by depleting 
maternal complement with cobra venom factor and blocking antibodies. We moni-
tored their effects primarily by genotyping and histologic analyses.
Results: We narrowed the critical period of the complement effect from 6.5 to 
8.5 days post- coitus (dpc), which is immediately after the conceptus is exposed to 
maternal blood. Deposition by 5.5 dpc of maternal C3b on the placental vasculature 
lacking Crry−/− yielded loss of the conceptus by 8.5 dpc. Fusion of the allantois to the 
chorion during placental assembly did not occur, fetal vessels originating in the al-
lantois did not infiltrate the chorioallantoic placenta, the chorionic plate failed to de-
velop, and the labyrinthine component of the placenta did not mature.
Conclusion: Our data are most consistent with the deposition of C3b being responsi-
ble for the failure of the allantois to fuse to the chorion leading to subsequent con-
ceptus demise.
K E Y W O R D S
alternative pathway, C3b deposition, complement membrane regulatory activity deficiency, 
complement system, conceptus demise, Crry, fusion of the allantois to the chorion
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activity (Figure 1B). Absence of these normal regulators of the AP 
are the cause of a number of human diseases, including atypical he-
molytic uremic syndrome (aHUS),1-6 C3 glomerulopathies (C3GN),1-6 
age- related macular degeneration (AMD),7-11 and protein- losing 
enteropathy.12
Crry is a widely expressed type 1 transmembrane protein in ro-
dents that downregulates the AP. It has strong cofactor activity for 
C3b and moderate decay accelerating activity for the classical path-
way.13-15 Crry’s broad expression profile and regulatory activities 
are similar to membrane cofactor protein (MCP/CD46) in primates 
(Figure 1B).16 MCP has a limited expression profile in rodents, being 
present primarily on the inner acrosomal membrane of spermato-
zoa.9,16-18 Crry−/− concepti produced by Crry+/− × Crry+/− matings 
are attacked by the maternal AP leading to loss before 10 days.15 
Notably, Crry−/− pups can be rescued if the mother is deficient in any 
1 of the 4 components (C3, FB, FD, and properdin) of the AP (13-15 
and X. Wu and J.P. Atkinson, unpublished). Fetal loss that occurs 
is not dependent on antibody (μMT−/− background) or the classical 
or lectin pathway of complement (C4−/− background).13 Moreover, 
demise is not mediated by the MAC, as the C6- deficient mouse con-
ceptus does not rescue the demise phenotype.19 However, C5a may 
play a minor role: C5−/− background led to ~5% of offspring being 
Crry−/− although much less than the expected 25% of offspring.13 
These results indicate that fetal loss occurs primarily through AP- 
directed events, prior to formation of the C5 convertase and the 
membrane attack complex.
Herein, we test the hypothesis that the ability of C3b to en-
gage the AP feedback loop in the absence of proper membrane 
regulation induces the placental lesion yielding the demise of the 
Crry−/− mouse. Specifically, we surmise that a reduction in mater-
nal AP activity at ~6.5 days post- coitus (dpc) would prevent con-
ceptus demise. The mouse blastocyst enters the uterus at 4.5 dpc 
yet the conceptus is not directly exposed to maternal blood until 
5.0- 6.5 dpc.20 As early as 6.5 but completely by 7.5 dpc, the ec-
toplacental cone cells that will evolve into the chorioallantoic pla-
centa are bathed in maternal blood, thereby exposing to proteins 
of the complement cascade. Neutrophil depletion and C3a recep-
tor blockade failed to rescue the conceptus. Overall, the results 
further suggest that C3b deposition is responsible for the loss of 
the conceptus.13-15,19
2  | MATERIAL S AND METHODS
2.1 | Mouse breeding and genotyping
Mice were bred and maintained under pathogen- free conditions at 
Washington University School of Medicine (WUSM) in St. Louis, 
MO in accordance with institutional animal care guidelines. The 
Crry knockout mouse was originally generated by Molina and col-
leagues14 and has been maintained at WUSM. The Crry−/− allele was 
genotyped by PCR as described.15 The C3aR knockout mouse was a 
gift from Richard Wetsel (University of Texas, Houston) and geno-
typed by PCR.
2.2 | Timed matings and harvesting embryos
After female mice were placed in the male’s cage, each subse-
quent day the female was checked for a vaginal plug. The day of 
plug observance was assigned 0.5 dpc. Mice were expected to de-
liver at 19.5 dpc. Pregnant mice were sacrificed by CO2 asphyxia-
tion in accordance with institutional guidelines. The uterus was then 
removed and each implantation site was separated surgically. The 
muscular uterus was removed under a dissecting microscope while 
the implantation site was placed in cold PBS. Pregnant mice were 
F IGURE  1 Alternative pathway of complement activation: 
feedback loop and regulation by cofactor activity. A, Four 
plasma proteins, C3, factor B (FB), factor D (FD), and properdin 
(P) assemble into the AP C3 convertase. C3 convertase has a 
continuous activity that generates a basal level of C3b. C3b 
engages the zymogen Factor B (FB) that is then cleaved by the 
serine protease Factor D (FD) to generate Bb and Ba. Bb remains 
bound to C3b while Ba is liberated (not shown). C3bBb is an active, 
albeit transient, AP enzyme complex that cleaves C3 to form C3a 
and C3b. C3a is a small peptide anaphylatoxin when released. C3b 
covalently binds to a nearby target (T) surface forming an ester 
linkage. Properdin binds to and stabilizes the C3bBb complex, 
increasing the half- life 5- to 10fold. Thus, the cleavage of C3 to 
C3b may result in a potent positive feedback amplification loop. 
The AP C5 convertase (C3b)2 BbP (not shown) cleaves C5 to 
C5a and C5b. C5a is a potent anaphylatoxin. C5b binds C6 and 
C7 and C5b,6,7 complex attaches to a membrane. The binding 
of C8 followed by multiple C9s then completes the formation of 
the membrane attack complex (MAC), which has the capacity to 
perturb cellular membranes including generating pores to lyse cells. 
B, Crry mediates membrane cofactor activity in the mouse. After 
Crry binds to C3b, then Factor I (FI), a plasma serine protease, can 
now cleave C3b to iC3b. iC3b has no hemolytic potential because it 
does not engage FB to initiate the feedback loop. Crry has intrinsic 
complement regulatory activity in that it primarily acts on the same 
cell on which it is expressed32
     |  3 of 11TRIEBWASSER ET Al.
routinely sacrificed at day 11.5 dpc. Implantation sites, including the 
concepti and extraembryonic membrane surrounded by decidua, 
were weighed to confirm the dpc. Genotyping was performed on 
each litter. To accomplish this, the conceptus was removed, washed 
7× in cold PBS in a microtiter plate, and digested in proteinase K 
(20 μg/mL) overnight at 55°C. DNA was precipitated, suspended in 
10 mmol/L Tris, 0.1 mmol/L EDTA, and then analyzed by PCR as de-
scribed previously.15
2.3 | Transcardial perfusion
Mice were anesthetized with ketamine/xylazine (ketamine from 
Henry Schein, Dublin, OH; xylazine from Department of Comparative 
Medicine, WUSM, St. Louis, MO). Transcardial perfusion with 50 mL 
of Dulbecco’s phosphate- buffered saline (DPBS; Sigma- Aldrich, 
St. Louis, MO) containing 20 U/mL of heparin (Sigma- Aldrich) was 
performed to remove plasma and red blood cells (RBCs) from the 
vasculature.
2.4 | Frozen section histology
Implantation sites, harvested as above, were dehydrated in 20% su-
crose overnight at 4°C, flash frozen in optimal cutting temperature 
(Sakura USA, Torrance, CA) with 2- methylbutane, and cooled with 
dry	 ice.	 Cassettes	 were	 stored	 at	 −80°C.	 Frozen	 sections	 (7	μm) 
were prepared on a Leica CryoStat. For granulocyte- differentiation 
antigen- 1 (Gr- 1) staining, frozen slides were fixed in pre- chilled 
acetone at room temperature (RT). Endogenous peroxidase was 
quenched with 0.3% H2O2 (Sigma- Aldrich) in methanol (Fisher 
Scientific, St. Louis, MO). Blocking was performed in PBS, 1% BSA, 
5% mouse serum, and 5% goat serum. RB6- 8C5 (BioXCell 3.5 mg/
mL, a rat monoclonal anti- mouse Gr- 1 Ab) was used at a dilution of 
1:500 in the blocking buffer. Another anti- Gr- 1 Ab (1A8) was used 
at 1:500 (BioXCell). The secondary Ab was a goat anti- rat light chain 




Implantation sites were fixed in 10% formalin overnight, embed-
ded in paraffin, 8 μm sections were rehydrated, antigen retrieval 
was performed, non- specific binding was blocked, and specific im-
munostaining was conducted as described below. In the case of 
Crry staining, antigen retrieval was performed in 10 mmol/L citric 
acid (anhydrous; Sigma- Aldrich), 0.05% Tween- 10, pH 6.0 in a pres-
sure cooker for 3 minutes. Blocking and staining were performed in 
1% BSA, 10% donkey serum, and 5% mouse serum in PBS. Rabbit 
anti-	Crry	 (1:1000;	 provided	 by	 V.	 Michael	 Holers,	 Division	 of	
Rheumatology, University of Colorado School of Medicine, Aurora, 
CO) was placed in blocking buffer overnight. Donkey anti- rabbit 
HRP (Jackson Immunoresearch) was used at 1:200. Staining was 
visualized with diaminobenzidine (DAB).
For trophoblast staining, 7.5 dpc implantation sites were collected 
as described above. Antigen retrieval was accomplished with 10 mmol/L 
Tris- EDTA pH 9.0 for 3 minutes in a pressure cooker. Staining was ac-
complished with TROMA- I (1:50 dilution of hybridoma supernatant; 
Developmental Studies Hybridoma Bank, University of Iowa) and goat 
anti- rat light chain horseradish peroxidase (HRP). Staining was visual-
ized with DAB. Controls employed a second Ab only.
2.6 | FACS analysis of cells derived from 7.5 dpc 
implantation sites
Implantation sites were harvested as described above. Each site was 
cut into 12 pieces and placed in RPMI 5% fetal bovine serum (FBS). 
These pieces were digested in RPMI containing 5% FBS, 300 μg/
mL collagenase F (Sigma- Aldrich), 200 μg/mL collagenase L (Sigma- 
Aldrich), 500 μg/mL Dispase (Gibco), and 2 U/mL DNase- 1 (Roche) 
at 37°C for 30- 45 minutes with a magnetic stir bar for agitation. 
Cells were passed over a 70 μm strainer (BD) to create a single- 
cell suspension. Implantation sites were washed in DPBS, 1% FBS, 
25 mmol/L EDTA. Cells were stained for FACS with anti- CD45 (30- 
F11, BD), anti- CD11b (M1/70, BD), anti- Gr- 1 (RB6- 8C5, BD), and rab-
bit anti- Crry followed by a donkey anti- rabbit DyLight 488 (Jackson 
ImmunoResearch). Blocking for FACS was carried out employing 
DPBS, 1% FBS, 25 mmol/L EDTA with 5% donkey serum, and 5% 
mouse serum. Cells were examined employing a FACScan (BD) retro-
fitted with a Cytek Upgrade.
2.7 | Cobra venom factor (CVF) treatment
Cobra venom factor (Quidel, A600) was administered intraperito-
neally (20 μg/mouse) with a 31G insulin syringe (Terumo). Depletion 
of C3 occurs in <1 hour. C3 hemolytic and antigenic activity is un-
detectable for up to 3- 4 days and then there is a gradual increase to 
normal levels over approximately a week.21,22
2.8 | Neutrophil depletion
Neutrophils were depleted by intraperitoneal injection (IP) injec-
tion of RB6- 8C5, a rat IgG2b mAb against Gr- 1 (Ly6G/C). A 250 μg 
dose of this Ab depleted neutrophils in the periphery for 5 days and 
a 500 μg dose depleted for 6 days. Both doses are followed by a re-
bound neutrophilia (approximately a doubling of pre- depletion lev-
els), which we were unable to overcome with an additional IP dose 
4 days after the first dose. 1A8 is a second anti- Gr- 1 rat IgG2a Ab 
(BioXCell). A 500 μg dose of 1A8 depleted ~50% of the neutrophils 
when the peripheral blood was assayed at 72 hours.
In the initial experiments, we used RB6- 8C5 that was a gift from 
Emil Unanue (Washington Univ. School of Medicine, Department 
of Pathology and Immunology, St. Louis, MO).23 RB6- 8C5 was also 
produced within the laboratory by hybridoma cells. The mAb was 
purified from supernatants on a protein G column and then dialyzed 
against PBS. RB6 was also purchased from BioXCell (West Lebanon, 
NH).
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3  | RESULTS
3.1 | Timing of AP activity required for conceptus 
loss and depletion of the AP by CVF
Crry−/− products of conception are known to undergo demise 
before 10.5 dpc with maternal AP components playing a critical 
role.13-15,24 We sought to determine when the lethal AP activity oc-
curred and we chose treatments that could suspend AP activity after 
implantation.	CVF	is	a	C3b	analog	that	forms	a	stable	AP	convertase	
with	Bb	(CVFBb),	and	unlike	host	AP	C3	convertases,	CVFBb	is	not	
susceptible to inhibitory activity of the complement regulators.25 
Consequently,	 treatment	with	CVF	 rapidly	depletes	 circulating	C3	
and diminishes FB, fully exhausting complement activity.22
We depleted AP by injecting 20 μg	CVF	IP	into	newly	pregnant	mice	
and examined Western Blots of serum for C3. This approach yielded no 
detectable C3 for the next 4 days, with C3 levels returning to 50% of 
normal by 7 days post- injection. The fetuses were genotyped and the 
placenta	examined	at	11.5	dpc.	CVF	treatment	administered	between	
3.5 and 5.5 dpc rescued Crry−/− mice, compared to controls (Table 1). 
Treatment	at	6.5	or	7.5	dpc	led	to	~50%	rescue.	Of	note,	CVF	treatment	
had no adverse effect on pup survival, as Crry−/− pups were born to 
CVF-	treated	mothers	similar	to	controls	(Table	2),	matured	as	expected,	
and Crry−/− females were fertile (not shown).
3.2 | Effects of depletion of properdin by  
anti- properdin antibody
Properdin (P) is critical for AP activity in many systems as this posi-
tive regulator stabilizes the C3 convertase 5- to 10 fold.26-28 The 
P −/− background rescues Crry−/− viability,24 as does FB−/−,13 FD−/− (X. 
Wu and J.P. Atkinson, unpublished) and C3−/−.14 A treatment of newly 
pregnant mice with a rabbit polyclonal Ab to mouse properdin also 
restored Crry−/− viability (Table 3).29
Treatment with a neutralizing anti- mouse properdin mAb also 
rescued Crry−/− concepti.29 Specifically, treatment with 1 mg of the 
H4 hamster anti- mouse properdin mAb at 6.5 and 7.5 dpc resulted 
in 32% Crry−/− pup viability, compared to the expected 0% without 
treatment (P = .0005, 25 pups, 4 litters) and the 50% viability ex-
pected from Crry+/− female × Crry−/− male.
3.3 | Histology of the implantation site
The above results showed that conception loss was prevented if 
AP inhibition began before 6.5 dpc, and a partial effect existed 
if inhibition began by 6.5- 7.5 dpc. The ectoplacental cone cells 
of the mouse are precursors to the labyrinthine trophoblast in 
the placenta. The cone cells contact maternal RBCs as early as 
TABLE  1 Treatment	with	CVF	prior	to	8.5	dpc	rescues	Crry−/− implantationsa
dpc of treatment 
(litters)








3.5 (3) 26/27 1/27 4 Yes**
4.5 (2) 19/20 1/20 5 Yes**
5.5 (1) 10/10 0/10 0 Yes
6.5 (2) 13/15 2/15 13 Partial*
7.5 (3) 24/27 3/27 11 Partial**
8.5 (3) 17/25 8/25 32 No
CVF,	cobra	venom	factor;	dpc,	day	post-	coitus.
aData derived from crosses between Crry+/− females and Crry+/− males. Approximately, 25% of the resulting concepti would be expected to be Crry−/− 
and	resorbed	in	the	absence	of	CVF	treatment.	Implantation	sites	were	evaluated	and	genotyped	at	11.5	dpc.
**P < .01 and *P < .05 compared with the proportion of full size implantations if not treated. The 5.5 dpc had only 1 treated litter; a statistical test was 
not performed. Partial rescue indicates the number of resorbed implantations was between a full rescue and no rescue.
dpc of treatment 
(litters) 
Crry−/− pupsb (fraction 
of total)
Crry−/− pups (% of 
total) Crry−/−pups rescued
3.5 (3) 7/17 41 Yes***
4.5 (2) 10/16 63 Yes***
5.5 (5) 14/26 53 Yes***
CVF,	cobra	venom	factor;	dpc,	day	post-	coitus.
aData derived from crosses between Crry+/− females and Crry−/− males. Approximately, 50% of the 
concepti are expected to be Crry−/−. Pups were genotyped at birth. No Crry−/− pups were born when 
CVF	treatment	was	omitted	(7	litters).
bCrry−/− pups were normal in size and developed comparably to wild- type mice. The Crry−/− females 
were fertile and delivered normal litters when crossed to Crry+/+ males.
***P	≤	.005	 compared	with	 the	 expected	 percentage	 (0%)	 of	Crry−/−	 pups	 in	 the	 absence	of	CVF	
treatment.
TABLE  2 Treatment	with	CVF	enables	
the birth of Crry−/− pupsa
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5.5 dpc and are bathed in blood at 6.5 dpc.20 The yolk sac pla-
centa offers nutrition to the conceptus until 9.5 dpc, when the 
labyrinthine placenta assumes the major role in maternal- fetal ex-
change (Figure 2). Importantly, we observed that at 8.5 dpc there 
was a substantial difference in the size of the allantoic vessels, a 
lack of proliferation of the labyrinthine trophoblasts, and smaller 
than control embryos in Crry−/− gestations (Figure 3). Moreover, 
the Crry−/− implantations at 9.5 dpc failed to evolve like controls, 
with an undeveloped labyrinth and unexpanded chorioallantoic 
vessels (Figure 4).
3.4 | Anaphylatoxin C3a and its receptor are not 
required for Crry−/− conceptus loss
A role for C3a in conception loss has not been studied. We tested 
whether C3a:C3aR signaling directed the demise of the Crry−/−. 
C3a receptor has been shown to be important in experimental 
lupus nephritis.29 We mated Crry+/−C3aR−/− × Crry+/−C3aR−/− mice 
hypothesizing that deficiency of C3aR would rescue the Crry−/− em-
bryos. The preceding cross was predicted to have 25% Crry−/− pups 
among the offspring, however, among the 59 viable pups, we ob-
served no Crry−/− pups, indicating that the absence of C3aR was not 
sufficient to rescue Crry−/− concepti (Table 4).
3.5 | Neutrophils are not required for Crry- /- 
conceptus loss
In the APLS model of embryonic lethality,30 complement- mediated 
damage is dependent on neutrophils. We observed neutrophils sur-
rounding Crry−/− implantation sites on 7.5 dpc, but the impact on 
conception viability has not been established.13 We pursued this 
issue and first confirmed, by both FACS and immunohistochemistry, 
that neutrophils surrounded Crry−/− and Crry+/− implantation sites 
at 7.5 dpc (Figure 5). Notably, we observed no correlation between 
genotype and the number of neutrophils present. Also, there was no 
correlation between CD45+ as a marker of hematopoietic- derived 
TABLE  3 Transient inhibition of properdin rescues Crry−/− implantationsa
dpc of treatment (litters)








3.5 + 7.5 (2)b 15/17 2/17 12 Yes***
6.5 + 7.5 (3)b 20/24 4/24 17 Yes***
6.5 + 7.5 (2)c 12/17 5/17 29 No**
7.5 (3) 14/29 15/29 52 No
dpc, day post- coitus.
aData derived from crosses between Crry+/− females and Crry−/− males. Approximately, 50% of the resulting concepti would be expected to be Crry−/− 
and resorbed in the absence of anti- properdin treatment. Implantation sites were evaluated and genotyped at 11.5 dpc.
bOne milligram rabbit anti- properdin on both days.
cFive hundred microgram rabbit anti- properdin on both days.
***P < .005 and **P < .05 compared with the proportion of full size implantations if not treated.
F IGURE  2 Maternal blood bathes the 
ectoplacental cone trophoblast at 7.5 dpc. 
A, Maternal red blood cells (RBCs) bathe 
the ectoplacental cone (epc). B, RBCs are 
visible at both ends of the amnionic sac. 
C, Among the epc are trophoblast cells 
that immunostain (brown) for cytokeratin 
8 (TROMA- I). D, Gross dissection of 
7.5 dpc implantation site shows blood at 
both ends. All panels are from a 7.5 dpc 
litter, sacrificed without perfusion to 
retain maternal blood. Histology is from 
formalin- fixed, paraffin- embedded 
sections. A,B, are hematoxylin and eosin 
stained. C, Immunocytochemical staining 
by HRP- conjugated anti- cytokeratin 8. 
em, embryo; epc, ectoplacental cone; tgc, 
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cells or CD11b+ Gr- 1− cells in either Crry−/− or Crry+/− genotypes at 
7.5 dpc. Neutrophils were present at implantation sites of all tested 
strains.
We next treated pregnant mice at 4.5 dpc with RB6- 8C5, a mAb 
that depletes Gr- 1 (Ly- 6C/G) positive cells, the majority of which 
are neutrophils, and we confirmed the absence of neutrophils at 
F IGURE  3 Crry−/− embryos die at 8.5 dpc due to a failure of the allantoic vessels to attach to the chorionic plate. According to the 
Theiler classification,19 the allantois contacts the chorion between 7.5 and 8.75 dpc. A, The allantois of Crry+/− embryos attaches to the 
ectoplacental cone at 8.5 dpc and expands the chorionic plate. Notably, Crry+/− trophoblast giant cells immunostain positive (brown) for Crry. 
B, The allantois of Crry−/− embryos, however, does not attach properly to the ectoplacental cone at 8.5 dpc and the allantoic vessels and the 
trophoblast fail to develop normally. Crry−/− trophoblast giant cells do not stain positive (brown) for the Crry protein. Areas of Crry positive 
cells in the decidua are not of fetal origin but are maternal blood cells within maternal vessels. All sections are formalin- fixed paraffin- 
embedded sections. a, allantois; av, allantoic vessels; cp, chorionic plate; d, decidua; em, embryo; tgc, trophoblast giant cell
(A) (B)
F IGURE  4 Embryos at 9.5 dpc fail to develop allantoic vessels and labyrinth. A, Crry+/+ embryo is fully developed at 9.5 dpc. Its allantois 
has fused with the mesoderm overlaying the ectoplacental cone. Black bar delineates the labyrinth. B, The allantoic vessels (black bar) have 
expanded and nucleated fetal red blood cells (RBCs) are visible passing within the vessels into the labyrinth where the trophoblast interfaces 
with maternal RBCs without nuclei (200× of box in A). C, Crry+/+ embryo at 9.5 dpc (20×). D, Trophoblast giant cells strongly express Crry 
(brown, rabbit anti- Crry) and separate the maternal decidua from the labyrinth. E, Crry−/− embryo at 9.5 dpc has failed to develop. F, The 
Crry−/− trophoblast giant cells do not stain for Crry, the labyrinth has not developed and allantoic vessels have not expand at 9.5 dpc. av, 
























pups (fraction of 
total)
Crry−/− C3aR−/− 
pups (% of total) Total pups Crry−/− pups rescued
16/59 43/59 0/59 59 None
C3aR−/−, C3a receptor knockout mouse; dpc, day post- coitus.
aData derived from crosses between Crry+/− C3aR−/− females and Crry+/− C3aR−/− males. Pups were 
genotyped at birth. Approximately 25% of the concepti are expected to be Crry+/+, 50% Crry+/−, and 
25% Crry−/−. Loss of all Crry−/− concepti leads to approximately 66% Crry+/− and 33% Crry+/+ concepti. 
There was no statistical difference between what was observed with these crosses and 11 Crry+/− 
C3aR+/+ × Crry+/− C3aR+/+ control litters (P > .05).
TABLE  4 The C3aR−/− background does 
not rescue Crry−/− pupsa
F IGURE  5 Neutrophils are present around all embryos. A, Crry−/− embryos (left panel) have 3 cell populations when stained with anti- 
Crry and anti- CD45 Abs. Crry+CD45+ population (maternal hematopoietic- derived cells), Crry+CD45− population (maternal decidua- derived 
cells), and Crry− CD45− population (embryo- and trophoblast- derived cells). Crry+/− embryos (right panel) lack the Crry− CD45− population; 
the embryo and trophoblast- derived cells cluster with maternal decidua- derived cells. B, There is no trend towards different proportions of 
hematopoietic derived (CD45+) cells around Crry+/− versus Crry−/− embryos. C, The Crry+ CD45+ population contains Gr- 1+ CD11b+ positive 
cells, neutrophils. D, There is no difference in the proportion of neutrophils dependent upon genotype. E, Staining control for anti- Crry. 
Crry−/− splenocytes in red and Crry+/− in blue. F, There is no difference in the proportion of CD11b+ Gr- 1− cells dependent upon genotype 
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the sites of implantation at 7.5 dpc (Figure 6). Examination of the 
surviving concepti at 10.5 and 13.5 dpc (Table 5), along with ge-
notyping of litters (Table 6), indicated that neutrophil depletion 
by RB6- 8C5 did not improve Crry−/− viability. Similarly, deple-
tion of neutrophils by treatment of pregnant mice with an anti- 
Ly6G- specific Ab (1A8, 500 μg/mouse) had no detectable effect 
(Table 6). We concluded that neutrophils are not essential for loss 
of the Crry−/− embryos.
4  | DISCUSSION
The AP of the complement system is a constant sentinel, activating 
continuously on surfaces and in the fluid phase.15,31 Regulators on 
cell membranes and in plasma are essential to control the level of 
activation. Crry is widely expressed on the surface of mouse cells 
and carries cofactor activity.32 In plasma and on cellular debris, fac-
tor H (FH) performs a similar role. Crry is able via CA to permanently 
stop AP activation on cell membranes.33 In the Crry−/− mouse model, 
excessive AP activation leads to conceptus demise by 8.5 dpc of de-
velopment, highlighting the critical role played by regulators of the 
AP. Crry−/− pups can be rescued by down modulating the levels of the 
AP activating proteins in the mother.15
The data herein show that transient depletion of the AP, either 
with	CVF	or	an	anti-	properdin	Ab,	is	sufficient	to	rescue	Crry−/− con-
cepti. There is a critical window at 6.5- 7.5 dpc when AP activation 
leads	to	conceptus	loss.	In	the	case	of	CVF,	treatment	prior	to	this	
window produces full rescue, but treatment during this 24- hour 
period	rescues	about	one-	half	of	the	concepti.	Interestingly,	if	CVF	
is given at 3.5 dpc prior to implantation of the blastocyst into the 
decidua,	maternal	C3	levels	rise	to	~50%	by	7.5	dpc	(4	d	after	CVF	
treatment) but Crry−/− embryos survive. This replicates the finding 
F IGURE  6 Neutrophils are present around 7.5 dpc embryos and RB6- 8C5 depletes them from around embryos. A, Neutrophils are 
present around the embryo at 7.5 dpc (anti- Gr- 1 staining; 200×). B, This staining is specific for Gr- 1+ and is not present in the isotype control. 
C, At higher magnification (400×), the nuclear pattern characteristic of neutrophils can be seen inside of Gr- 1+ cells. D,E, Identical patterns 
are observed in staining for Gr- 1+ (RB6- 8C5, D) and Ly6G (1A8, E). F, Ly6G staining is specific to 1A8 and not seen in the isotype control. G- I, 
Neutrophil depletion with 500 μg RB6- 8C5 at 4.5 dpc leads to absence of neutrophils in the tissue at 7.5 dpc of Gr- 1+ (G) and Ly6G+ cells 
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that full blockade of the AP is not required for embryo survival, as 
haploinsufficiency of AP activating components will also rescue the 
concepti.15
4.1 | Timing of C3 deposition
C3 deposition on the ectoplacental cone of the Crry−/− mouse occurs 
at approximately 7.5 dpc.13,14 We propose this takes place because 
there is no membrane- based complement inhibitor on these cells. 
Decay- accelerating factor (DAF), a GPI- anchored regulator, is not 
expressed in the labyrinthine placenta until after ~10.5 dpc.13 Other 
C3 regulators of complement such as FH are present in maternal 
blood but they are unable to compensate for Crry deficiency. For 
example, FH is normal in Crry−/− mouse but this complement regu-
lator is insufficient to limit the diffuse AP activation observed on 
cells in the Crry−/− mouse.15 We surmise that the underlying cause 
of conceptus loss in this model is a dysregulated AP of complement 
activation on cell membranes.
4.2 | Mechanism of loss
In the Crry−/− mouse model, conceptus lethality is the result of in-
sufficient complement regulatory capacity. The current study was 
designed to identify the early events that contribute to the patho-
genesis in this system. Previous work employing knockout mice 
showed that fetal loss requires maternal AP components FB, FD, 
properdin, and C3, that is, all 4 components of the AP. Here, we 
extend these studies to demonstrate that depletion of maternal AP 
components	by	6.5	dpc,	utilizing	CVF	treatment	or	neutralization	of	
properdin with an Ab, rescues the Crry−/− embryo. Within the inher-
ent 0.5 dpc in the Theiler staging system, the ~6.5 dpc critical time 
period is when extraembryonic ectoplacental cone cells become 
bathed in maternal blood and, consequently, immersed in mater-
nal complement.20 Wild- type components of the developing laby-
rinthine placentas connect to the maternal vasculature by 8.5 dpc 
(Figures 2 and 3), and by 9.5 dpc the labyrinthine hemochorial pla-
centa replaces the yolk sac placenta to assume the major duty of 
supplying nutrients to the fetus. In the Crry−/− embryo, the fusion of 
the allantois to the chorion during labyrinthine assembly does not 
occur because the chorionic plate fails to develop and the labyrin-
thine trophoblast does not mature to be permeated by allantoic fetal 
vessels (Figures 2 and 3).
Previous investigations of placental maldevelopment in the 
Crry−/− model have ruled out involvement of Ab,14 major contribu-
tions of C4 and C6.13-15,19 We now show there is no role for neu-
trophils. Notably, maternal C5 deficiency has a limited restorative 
effect, suggesting a minor role for C5a.13-15,19 Thus, the Crry−/− 
model studies confirm a cause and effect relationship between 
complement regulatory deficiency leading to excess AP activity and 
aberrant placental development. Importantly, other mouse models 
demonstrate that placental insufficiency can occur through differ-
ent complement- dependent scenarios: in the APS model, human au-
toantibodies bind autoantigens in the mouse placenta where they 
activate complement34 while in the abortion- prone mating combi-
nation of CBA/J female × DBA/2 male complement is activated via 
the lectin pathway.35
The strengths of our study include the approaches that allowed 
us to identify that a deficiency of maternal C3aR or a lack of neu-
trophils does not prevent conceptus loss. A weakness is that we can 
only speculate that C3 deposition begins based on when maternal 
TABLE  5 Neutrophil depletion does not rescue Crry−/− implantations
Female × male
dpc of treatmenta 
(litters)





tions (% of total)
Crry−/− implanta-
tions rescuedb
Crry+/− × Crry+/− (25% 
Crry−/− expected)
RB6/5.5 (3) 19/27 8/27 30 No
RB6/6.5 (2) 13/17 4/17 24 No
PBS/6.5 (3) 17/25 8/25 32 No
Crry+/− × Crry−/− (50% 
Crry−/− expected)
RB6/4.5 (2) 6/14 8/14 57 No
RB6/4.5, 6.5 (2) 9/15 6/15 40 No
1A8/5.5 (3) 13/21 8/21 46 No
PBS, phosphate- buffered saline; dpc, day post- coitus.
aRB6- 8C5 (mAb anti- Gr1) 250 μg IP in Crry+/− × Crry+/− matings and 500 μg IP in Crry+/− × Crry−/− matings. 1A8 (mAb anti- Ly6G) 500 μg IP. Two dates 
listed for dpc indicates that the dose was given twice.
bNo treatment condition significantly differed from the expected rate of resorptions (P > .05). Implantation sites were examined and genotyped at 
11.5 dpc.










RB6/3.5 6/6 0/6 No
1A8/4.5 4/4 0/4 No
1A8/5.5 4/4 0/4 No
dpc, day post-coitus.
aData derived from crosses between Crry+/− females and Crry−/− males (1 
litter at each dpc of treatment). Approximately, 50% of the resulting con-
cepti would be expected to be Crry−/−. Pups were genotyped at birth.
bRB6- 8C5 (mAb anti- Gr1), 500 μg IP; 1A8 (mAb anti- Ly6G), 500 μg IP.
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blood is apparent and when complete rescue of Crry−/− concepti 
occurred	 in	our	CVF	experiments.	Our	 studies	combined	with	 the	
above discussion suggest that the detrimental effects of AP activity 
on the development of extraembryonic cells destined to form the 
labyrinthine placenta are mediated primarily by C3b and/or its deriv-
atives. We have previously extensively assessed the timing of C3b 
deposition on placental tissue in the normal and complement regula-
tory protein (Crry) deficient mice.14,15
4.3 | Could dysregulation of the AP of complement 
yield some forms of the preeclamptic phenotype?
Preeclampsia (PE) is a syndrome that associates with placental mal-
development in the first trimester, yielding placental dysfunction in 
the second half of pregnancy.36,37 The placenta is deemed a root 
cause for many of the variable phenotypes of PE and immune- based 
maternal- fetal incompatibilities contribute to some forms of the PE 
syndrome.38 Notably, patients with this syndrome show greater sys-
temic complement AP activity compared to normotensive women, 
but debate persists as to a cause- effect relationship of this find-
ing with the pathogenesis of the disorder. We recently presented 
studies of cohorts of autoimmune and non- autoimmune PE patients 
that demonstrate an association of PE with dysfunctional comple-
ment regulatory genes, including FI, FH, and MCP.39,40 These find-
ings suggest that some cases of PE may be initiated by insufficient 
regulatory capacity and excessive AP complement activity during 
development, predisposing the placenta to maldevelopment, injury, 
or both during gestation. Further investigation is needed to deter-
mine the scope of excessive complement activity in human placental 
dysfunction.
ACKNOWLEDG EMENTS
Research reported in this publication was supported by the 
National Institutes of Health under award number NIAID R01 
AI051436 (DH); NIGMS 2 RO1 GM099111, NIAID R01 AI041592 
(XW, PB, JPA); Ruth L. Kirschstein Individual Predoctoral NRSA 
F30HL103072 (MT); and the Hybridoma Center and Protein 
Production and Purification Facility of the Rheumatic Diseases 
Core Center NIAMS P30 AR048335 (PB, DH, JPA). The content 
is solely the responsibility of the authors and does not necessarily 
represent the official views of the National Institutes of Health. 
DMN is supported by the Barnes- Jewish Hospital Foundation, St. 
Louis, MO.
ORCID
John P. Atkinson  http://orcid.org/0000-0002-2514-3441 
R E FE R E N C E S
 1. Kavanagh D, Richards A, Atkinson JP. Complement regulatory genes 
and hemolytic uremic syndromes. Annu Rev Med. 2008;59:293-309. 
 2. Hawfield A, Iskandar SS, Smith RJ. Alternative pathway dysfunction 
in kidney disease: a case report and review of dense deposit disease 
and C3 glomerulopathy. Am J Kidney Dis. 2013;61:828-831.
 3. Smith RJ, Harris CL, Pickering MC. Dense deposit disease. Mol 
Immunol. 2011;48:1604-1610.
 4. Noris M, Remuzzi G. Glomerular diseases dependent on comple-
ment activation, including atypical hemolytic uremic syndrome, 
membranoproliferative glomerulonephritis, and C3 glomerulopa-
thy: core curriculum 2015. Am J Kidney Dis. 2015;66:359-375.
 5. Kaplan BS, Ruebner RL, Spinale JM, Copelovitch L. Current treat-
ment of atypical hemolytic uremic syndrome. Intractable Rare Dis 
Res. 2014;3:34-45.
 6. Loirat C, Fakhouri F, Ariceta G, et al. An international consensus ap-
proach to the management of atypical hemolytic uremic syndrome 
in children. Pediatr Nephrol. 2016;31:15-39.
 7. Ambati J, Atkinson JP, Gelfand BD. Immunology of age- related 
macular degeneration. Nat Rev Immunol. 2013;13:438-451.
 8. Clark SJ, Bishop PN. Role of factor H and related proteins in regu-
lating complement activation in the macula, and relevance to age- 
related macular degeneration. J Clin Med. 2015;4:18-31.
 9. Schramm EC, Clark SJ, Triebwasser MP, Raychaudhuri S, Seddon 
JM, Atkinson JP. Genetic variants in the complement system predis-
posing to age- related macular degeneration: a review. Mol Immunol. 
2014;61:118-125.
 10. Anderson DH, Radeke MJ, Gallo NB, et al. The pivotal role of 
the complement system in aging and age- related macular de-
generation: hypothesis re- visited. Prog Retin Eye Res. 2010;29: 
95-112.
	11.	 Khandhadia	 S,	 Cipriani	 V,	 Yates	 JR,	 Lotery	 AJ.	 Age-	related	 mac-
ular degeneration and the complement system. Immunobiology. 
2012;217:127-146.
 12. Ozen A, Comrie WA, Ardy RC, et al. CD55 deficiency, early- 
onset protein- losing enteropathy, and thrombosis. N Engl J Med. 
2017;377:52-61.
 13. Mao D, Wu X, Deppong C, et al. Negligible role of antibodies and 
C5 in pregnancy loss associated exclusively with C3- dependent 
mechanisms through complement alternative pathway. Immunity. 
2003;19:813-822.
	14.	 Xu	C,	Mao	D,	Holers	VM,	Palanca	B,	Cheng	AM,	Molina	H.	A	critical	
role for the murine complement regulator Crry in fetomaternal tol-
erance. Science. 2000;287:498-501.
 15. Wu X, Spitzer D, Mao D, Peng SL, Molina H, Atkinson JP. Membrane 
protein Crry maintains homeostasis of the complement system. J 
Immunol. 2008;181:2732-2740.
 16. Riley RC, Kemper C, Leung M, Atkinson JP. Characterization of 
human membrane cofactor protein (MCP; CD46) on spermatozoa. 
Mol Reprod Dev. 2002;62:534-546.
 17. Riley RC, Tannenbaum PL, Abbott DH, Atkinson JP. Cutting Edge: 
inhibiting measles virus infection but promoting reproduction: an 
explanation for splicing and tissue- specific expression of CD46. J 
Immunol. 2002;169:5405-5409.
	18.	 Riley-Vargas	RC,	Lanzendorf	S,	Atkinson	JP.	Targeted	and	restricted	
complement activation on acrosome- reacted spermatozoa. J Clin 
Invest. 2005;115:1241-1249.
 19. Ruseva MM, Hughes TR, Donev RM, et al. Crry deficiency in com-
plement sufficient mice: C3 consumption occurs without associ-
ated renal injury. Mol Immunol. 2009;46:803-811.
 20. Theiler K. The House Mouse.	 Berlin,	 Heidelberg:	 Springer	 Verlag,	
1989.
 21. Wu X, Xu TQ, Atkinson JP. Properdin homeostasis requires turn-
over of the alternative complement pathway. Proc Natl Acad Sci 
USA. 2010;107:19444-19448.
	22.	 Xu	Y,	Ma	M,	Ippolito	GC,	Schroeder	HW	Jr,	Carroll	MC,	Volanakis	
JE. Complement activation in factor D- deficient mice. Proc Natl 
Acad Sci USA. 2001;98:14577-14582.
     |  11 of 11TRIEBWASSER ET Al.
 23. Rogers HW, Unanue ER. Neutrophils are involved in acute, nonspe-
cific resistance to Listeria monocytogenes in mice. Infect Immun. 
1993;61:5090-5096.
 24. Kimura Y, Zhou L, Miwa T, Song WC. Genetic and therapeutic tar-
geting of properdin in mice prevents complement- mediated tissue 
injury. J Clin Invest. 2010;120:3545-3554.
 25. Cochrane CG, Muller-Eberhard HJ, Aikin BS. Depletion of plasma 
complement in vivo by a protein of cobra venom: its effect on vari-
ous immunologic reactions. J Immunol. 1970;105:55-69.
 26. Fearon DT, Austen KF. Properdin: binding to C3b and stabilization of 
the C3b- dependent C3 convertase. J Exp Med. 1975;142:856-863.
 27. Kemper C, Atkinson JP, Hourcade DE. Properdin: emerging roles of a 
pattern- recognition molecule. Annu Rev Immunol. 2010;28:131-155.
 28. Kemper C, Hourcade DE. Properdin: new roles in pattern recogni-
tion and target clearance. Mol Immunol. 2008;45:4048-4056.
 29. Bertram P, Akk AM, Zhou HF, Mitchell LM, Pham CT, Hourcade DE. 
Anti- mouse properdin TSR 5/6 monoclonal antibodies block com-
plement alternative pathway- dependent pathogenesis. Monoclon 
Antib Immunodiagn Immunother. 2015;34:1-6.
 30. Girardi G, Berman J, Redecha P, et al. Complement C5a receptors 
and neutrophils mediate fetal injury in the antiphospholipid syn-
drome. J Clin Invest. 2003;112:1644-1654.
 31. Lachmann PJ. The amplification loop of the complement pathways. 
Adv Immunol. 2009;104:115-149.
 32. Kim YU, Kinoshita T, Molina H, et al. Mouse complement regula-
tory protein Crry/p65 uses the specific mechanisms of both human 
decay accelerating factor and membrane cofactor protein. J Exp 
Med. 1995;181:151-159.
 33. Miwa T, Zhou L, Hilliard B, Molina H, Song WC. Crry, but not CD59 
and DAF, is indispensable for murine erythrocyte protection in vivo 
from spontaneous complement attack. Blood. 2002;99:3707-3716.
	34.	 Holers	VM,	Girardi	G,	Mo	L,	et	al.	Complement	C3	activation	is	re-
quired for antiphospholipid antibody- induced fetal loss. J Exp Med. 
2002;195:211-220.
 35. Rahmati M, Petitbarat M, Dubanchet S, Bensussan A, Chaouat G, 
Ledee N. Colony stimulating factors 1, 2, 3 and early pregnancy 
steps: from bench to bedside. J Reprod Immunol. 2015;109:1-6.
 36. Dekker GA, Sibai BM. Etiology and pathogenesis of preeclampsia: 
current concepts. Am J Obstet Gynecol. 1998;179:1359-1375.
 37. Zhang J, Meikle S, Trumble A. Severe maternal morbidity associ-
ated with hypertensive disorders in pregnancy in the United States. 
Hypertens Pregnancy. 2003;22:203-212.
 38. Lynch AM, Salmon JE. Dysregulated complement activation as a 
common pathway of injury in preeclampsia and other pregnancy 
complications. Placenta. 2010;31:561-567.
 39. Salmon JE, Heuser C, Triebwasser M, et al. Mutations in comple-
ment regulatory proteins predispose to preeclampsia: a genetic 
analysis of the PROMISSE cohort. PLoS Med. 2011;8:e1001013.
	40.	 Mohlin	FC,	Mercier	E,	Fremeaux-Bacchi	V,	et	al.	Analysis	of	genes	
coding for CD46, CD55, and C4b- binding protein in patients with 
idiopathic, recurrent, spontaneous pregnancy loss. Eur J Immunol. 
2013;43:1617-1629.
How to cite this article: Triebwasser MP, Wu X, Bertram P, 
Hourcade DE, Nelson DM, Atkinson JP. Timing and 
mechanism of conceptus demise in a complement regulatory 
membrane protein deficient mouse. Am J Reprod Immunol. 
2018;80:e12997. https://doi.org/10.1111/aji.12997
